BioInvent International AB (BIX0) Stock Statistics & Valuation Metrics
Total Valuation
BioInvent International AB has a market cap or net worth of EUR 25.83M. The enterprise value is EUR 1.30B.
- Market Cap
- EUR 25.83M
- Enterprise Value
- EUR 1.30B
Share Statistics
BioInvent International AB has 65,804,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 65,804,360
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
BioInvent International AB’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -62.07%.
- Return on Equity (ROE)
- -0.60
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -62.07%
- Return on Capital Employed (ROCE)
- -0.63
- Revenue Per Employee
- 2.10M
- Profits Per Employee
- -3.08M
- Employee Count
- 108
- Asset Turnover
- 0.34
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioInvent International AB is -0.51. BioInvent International AB’s PEG ratio is 0.01.
- PE Ratio
- -0.51
- PS Ratio
- 6.26
- PB Ratio
- 1.24
- Price to FCF
- -0.55
- Price to Operating Cash Flow
- -0.56
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, BioInvent International AB had revenue of 226.50M and earned -332.86M in profits. Earnings per share was -5.06.
- Revenue
- 226.50M
- Gross Profit
- 226.50M
- Operating Income
- -351.39M
- Pretax Income
- -332.46M
- Net Income
- -332.86M
- EBITDA
- -331.52M
- Earnings Per Share (EPS)
- -5.06
Cash Flow
In the last 12 months, operating cash flow was -448.86M and capital expenditures -2.71M, giving a free cash flow of -451.58M billion.
- Operating Cash Flow
- -448.86M
- Free Cash Flow
- -451.58M
- Free Cash Flow per Share
- -6.87
Dividends & Yields
BioInvent International AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -180.35%
- Earnings Yield
- -194.76%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- -86.03%
- 50-Day Moving Average
- 1.93
- 200-Day Moving Average
- 2.14
- Relative Strength Index (RSI)
- 9.00
- Average Volume (3m)
- 637
Important Dates
BioInvent International AB upcoming earnings date is Mar 04, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
BioInvent International AB as a current ratio of 5.67, with Debt / Equity ratio of 1.74%
- Current Ratio
- 5.67
- Quick Ratio
- 5.56
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.05
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioInvent International AB has paid 397.00K in taxes.
- Income Tax
- 397.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
BioInvent International AB EV to EBITDA ratio is -0.09, with an EV/FCF ratio of -0.10.
- EV to Sales
- 1.13
- EV to EBITDA
- -0.09
- EV to Free Cash Flow
- -0.10
- EV to Operating Cash Flow
- -0.10
Balance Sheet
BioInvent International AB has EUR 224.56M in cash and marketable securities with EUR 19.33M in debt, giving a net cash position of EUR 205.24M billion.
- Cash & Marketable Securities
- EUR 224.56M
- Total Debt
- EUR 19.33M
- Net Cash
- EUR 205.24M
- Net Cash Per Share
- EUR 3.12
- Tangible Book Value Per Share
- EUR 3.06
Margins
Gross margin is 100.00%, with operating margin of -1241.98%, and net profit margin of -1217.66%.
- Gross Margin
- 100.00%
- Operating Margin
- -1241.98%
- Pretax Margin
- -1216.62%
- Net Profit Margin
- -1217.66%
- EBITDA Margin
- -1196.66%
- EBIT Margin
- -1241.98%
Analyst Forecast
The average price target for BioInvent International AB is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -83.45%
- EPS Growth Forecast
- -55.93%
